HFA Premium Access

Survival in HFpEF vs HFrEF patients after beta-blocker titration: New insights from the CIBIS-ELD trial

Congress Presentation

About the speaker

Professor Hans-Dirk Duengen

Scirent - Clinical Research and Science, Berlin (Germany)
1 presentation
0 follower

13 more presentations in this session

Morbidity, mortality, and cost impact of stage b and stage c heart failure: comparative analysis to underline the clinical and economic need for heart failure prevention strategy.

Speaker: Doctor S. James (Dublin, IE)


Effects of 5 years treatment with nebivolol, carvedilol and bisoprolol in heart failure patients

Speaker: Doctor G. Marazzi (Rome, IT)


MTP-131, a cardiolipin-targeting peptide, improves mitochondrial activity in the failing human heart

Speaker: Doctor B. Stauffer (Aurora, US)


Is the cohort of paradigm-hf representative of the real world population of patients with systolic heart failure?

Speaker: Doctor G. Rocha Rodrigues (Lisbon, PT)


Evidence-based medications in multi-ethnic Asian patients with heart failure are associated with better outcomes in spite of lower doses

Speaker: Doctor T. Teng (Singapore, SG)


Access the full session

Rapid Fire 3 - Chronic heart failure management

Speakers: Professor H. Duengen, Doctor S. James, Doctor G. Marazzi, Doctor B. Stauffer, Doctor G. Rocha Rodrigues...

About the event



21 May - 24 May 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb